Possible Pneumonia Stocks - signs of potential breakout
Emergent Biosolutions (EBS):
EBS is a clinical-stage biotechnology company developing a novel vaccine for pneumonia. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout. The stock is up over 20% in the past month, and it is trading above its 50-day and 200-day moving averages.
Vaxart (VXRT):
Vaxart is a clinical-stage biotechnology company developing a tablet-based vaccine for pneumonia. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout. The stock is up over 30% in the past month, and it is trading above its 50-day moving average.
Novavax (NVAX):
Novavax is a clinical-stage biotechnology company developing a vaccine for influenza. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout. The stock is up over 40% in the past month, and it is trading above its 50-day and 200-day moving averages.
Pfizer (PFE):
Pfizer is a large pharmaceutical company that develops and sells vaccines, including a vaccine for pneumonia. The company's stock is undervalued, and it is starting to show signs of a breakout. The stock is up over 10% in the past month, and it is trading above its 50-day moving average.
Merck & Co. (MRK): * Merck is a large pharmaceutical company that develops and sells vaccines, including a vaccine for pneumonia. The company's stock is undervalued, and it is starting to show signs of a breakout. The stock is up over 8% in the past month, and it is trading above its 50-day moving average.
These are just a few of the many stocks that may be undervalued and appear to be showing signs of potential breakout. It is important to do your own research before investing in any stock.
Please share your ideas or charts in the comments below.
Comment
⋅
Emergent Biosolutions (EBS): 4-hour Chart:
Comment
⋅
Vaxart (VXRT): 4-hour Chart:
Comment
⋅
Novavax (NVAX): 4-hour Chart:
Comment
⋅
Pfizer (PFE): 4-hour Chart:
Comment
⋅
Merck & Co. (MRK): 4-hour Chart:
Comment
⋅
$140 Dec 1 $145 Dec 29
Comment
⋅
(still in play) $140 Dec 1 $145 Dec 29 $153 Jan 3
Comment
⋅
(still in play) $140 Dec 1 $145 Dec 29 $153 Jan 3 $154 Jan 12
Comment
⋅
(still in play) $140 Dec 1 $145 Dec 29 $153 Jan 3 $154 Jan 12 $160 Feb 8
Comment
⋅
(still in play) (still in play) $140 Dec 1 $145 Dec 29 $153 Jan 3 $154 Jan 12 $160 Feb 8 $166.06 Feb 29